Skip to main content
Clinical Trials/NCT05117424
NCT05117424
Recruiting
N/A

The Impact of Cardiometabolic Factors on Coronary Artery and Cardiovascular Diseases: a Prospective Cohort Study

Ruijin Hospital1 site in 1 country3,000 target enrollmentJanuary 1, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Ruijin Hospital
Enrollment
3000
Locations
1
Primary Endpoint
Coronary plaque progression
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Systematic metabolic diseases are closely related to prevalence and progression of atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery disease compliacted with metabolic abnormalities such as diabtetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.

Detailed Description

CArdioMetabolism and Atherosclerotic PlaqUe progreSsion (CAMPUS) study is a single center, prospective cohort study to investigate the impact of cardiometabolic factors on coronary diseases. This study consecutively enrolls patients with coronary artery diseases complicatied with metabolic abnormalities, including diabetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.

Registry
clinicaltrials.gov
Start Date
January 1, 2017
End Date
December 31, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

RUIYAN ZHANG

Professor

Ruijin Hospital

Eligibility Criteria

Inclusion Criteria

  • Age 18-80 years
  • Established coronary artery disease or metabolic disorders, including:
  • Type 2 diabetes diagnosed by one of the following criteria:
  • HbA1c \>/= 6.5% Fasting plasma glucose \>/= 7.0 mmol/l (confirmed) 2h plasma glucose value during OGTT \>/= 11.1 mmol/l Already receiving glucose-lowering agents
  • Prediabetes
  • Chronic kidney disease
  • Hyperuricemia
  • Dyslipidemia

Exclusion Criteria

  • Severe liver failure (Child-Pugh grade B to C)
  • Severe anemia (hemoglobin \< 60g/L)
  • Familial hypercholesterolemia
  • Active malignant tumor
  • Active autoimmune diseases on corticosteroids
  • Acute or chronic infection
  • Life expectancy \< 1 year

Outcomes

Primary Outcomes

Coronary plaque progression

Time Frame: 12 months

Assessed by coronary angiography and QCA

Coronary lesion severity

Time Frame: 12 months

Assessed by coronary angiography and QCA

Secondary Outcomes

  • Coronary plaque characteristics(12 months)
  • Cardiovascular events(up to 5 years)

Study Sites (1)

Loading locations...

Similar Trials